Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results?

OBJECTIVES: This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to hepatic arterial infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex) in unresectable primary liver cancer. METHODS: Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kemeny, Nancy E., Schwartz, Lawrence, Gönen, Mithat, Yopp, Adam, Gultekin, David, D’Angelica, Michael I., Fong, Yuman, Haviland, Dana, Gewirtz, Alexandra N., Allen, Peter, Jarnagin, William R.
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2011
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3123741/
https://ncbi.nlm.nih.gov/pubmed/21677464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000324704
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados